Revolution Medicines, Inc. (RVMD) NASDAQ
151.31
-12.37(-7.56%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
151.31
-12.37(-7.56%)
Currency In USD
| Previous Close | 163.68 |
| Open | 161.23 |
| Day High | 162.76 |
| Day Low | 151.31 |
| 52-Week High | 166.5 |
| 52-Week Low | 34 |
| Volume | 3.68M |
| Average Volume | 2.98M |
| Market Cap | 32.17B |
| PE | -21.31 |
| EPS | -7.1 |
| Moving Average 50 Days | 131.48 |
| Moving Average 200 Days | 87.62 |
| Change | -12.37 |
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
GlobeNewswire Inc.
Feb 25, 2026 9:02 PM GMT
On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three additional Phase 3 trials planned to
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 9:05 PM GMT
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith,
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
GlobeNewswire Inc.
Feb 18, 2026 9:05 PM GMT
REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report fina